Beales PL, Elcioglu N, Woolf AS, Parker D, Flinter FA. New criteria for improved diagnosis of Bardet–Biedl syndrome: results of a population survey. J Med Genet. 1999;36(6):437–46.
Forsythe E, Kenny J, Bacchelli C, Beales PL. Managing Bardet–Biedl syndrome-now and in the future. Front Pediatr. 2018;6:23.
Castro-Sánchez S, Álvarez-Satta M, Valverde D. Bardet–Biedl syndrome: a rare genetic disease. J Pediatr Genet. 2013;2(2):77–83.
Lindstrand A, Frangakis S, Carvalho CM, Richardson EB, McFadden KA, Willer JR, et al. Copy-number variation contributes to the mutational load of Bardet–Biedl syndrome. Am J Hum Genet. 2016;99(2):318–36.
Geets E, Meuwissen MEC, Van Hul W. Clinical, molecular genetics and therapeutic aspects of syndromic obesity. Clin Genet. 2019;95(1):23–40.
Shamseldin HE, Shaheen R, Ewida N, Bubshait DK, Alkuraya H, Almardawi E, et al. The morbid genome of ciliopathies: an update. Genet Med. 2020;22(6):1051–60.
Forsythe E, Beales PL. Bardet–Biedl syndrome. Eur J Hum Genet. 2013;21(1):8–13.
Sherafat-Kazemzadeh R, Ivey L, Kahn SR, Sapp JC, Hicks MD, Kim RC, et al. Hyperphagia among patients with Bardet–Biedl syndrome. Pediatr Obes. 2013;8(5):e64-67.
Malhotra S, Sivasubramanian R, Srivastava G. Evaluation and management of early onset genetic obesity in childhood. J Pediatr Genet. 2021;10(3):194–204.
Pomeroy J, Krentz AD, Richardson JG, Berg RL, VanWormer JJ, Haws RM. Bardet–Biedl syndrome: weight patterns and genetics in a rare obesity syndrome. Pediatr Obes. 2021;16(2):e12703.
Huvenne H, Dubern B, Clement K, Poitou C. Rare genetic forms of obesity: clinical approach and current treatments in 2016. Obes Facts. 2016;9(3):158–73.
Yazdi FT, Clee SM, Meyre D. Obesity genetics in mouse and human: back and forth, and back again. PeerJ. 2015;3:e856.
Yang Y, van der Klaauw AA, Zhu L, Cacciottolo TM, He Y, Stadler LKJ, et al. Steroid receptor coactivator-1 modulates the function of POMC neurons and energy homeostasis. Nat Commun. 2019;10(1):1718.
Seo S, Guo DF, Bugge K, Morgan DA, Rahmouni K, Sheffield VC. Requirement of Bardet–Biedl syndrome proteins for leptin receptor signaling. Hum Mol Genet. 2009;18(7):1323–31.
Guo DF, Cui H, Zhang Q, Morgan DA, Thedens DR, Nishimura D, et al. The BBSome controls energy homeostasis by mediating the transport of the leptin receptor to the plasma membrane. PLoS Genet. 2016;12(2):e1005890.
Forsyth RL, Gunay-Aygun M. Bardet–Biedl syndrome overview. In: GeneReviews. https://www.ncbi.nlm.nih.gov/books/NBK1363/. Accessed 10 Aug 2022.
Haws RM, Gordon G, Han JC, Yanovski JA, Yuan G, Stewart MW. The efficacy and safety of setmelanotide in individuals with Bardet-Biedl syndrome or Alstrom syndrome: phase 3 trial design. Contemp Clin Trials Commun. 2021;22:100780.
Styne DM, Arslanian SA, Connor EL, Farooqi IS, Murad MH, Silverstein JH, et al. Pediatric obesity-assessment, treatment, and prevention: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2017;102(3):709–57.
August GP, Caprio S, Fennoy I, Freemark M, Kaufman FR, Lustig RH, et al. Prevention and treatment of pediatric obesity: an endocrine society clinical practice guideline based on expert opinion. J Clin Endocrinol Metab. 2008;93(12):4576–99.
Vos N, Oussaada SM, Cooiman MI, Kleinendorst L, Ter Horst KW, Hazebroek EJ, et al. Bariatric surgery for monogenic non-syndromic and syndromic obesity disorders. Curr Diab Rep. 2020;20(9):44.
Gantz MG, Driscoll DJ, Miller JL, Duis JB, Butler MG, Gourash L, et al. Critical review of bariatric surgical outcomes in patients with Prader–Willi syndrome and other hyperphagic disorders. Obesity (Silver Spring). 2022;30(5):973–81.
Haqq AM, Kebbe M, Tan Q, Manco M, Salas XR. Complexity and stigma of pediatric obesity. Child Obes. 2021;17(4):229–40.
Arnold M, Pandeya N, Byrnes G, Renehan PAG, Stevens GA, Ezzati PM, et al. Global burden of cancer attributable to high body-mass index in 2012: a population-based study. Lancet Oncol. 2015;16(1):36–46.
Ford ES, Moriarty DG, Zack MM, Mokdad AH, Chapman DP. Self-reported body mass index and health-related quality of life: findings from the behavioral risk factor surveillance system. Obes Res. 2001;9(1):21–31.
Jia H, Lubetkin EI. The impact of obesity on health-related quality-of-life in the general adult US population. J Public Health (Oxf). 2005;27(2):156–64.
Ramos Salas X, Forhan M, Caulfield T, Sharma AM, Raine KD. Addressing internalized weight bias and changing damaged social identities for people living with obesity. Front Psychol. 2019;10:1409.
Schwimmer JB, Burwinkle TM, Varni JW. Health-related quality of life of severely obese children and adolescents. JAMA. 2003;289(14):1813–9.
Sirtori A, Brunani A, Villa V, Berselli ME, Croci M, Leonardi M, et al. Obesity is a marker of reduction in QoL and disability. Sci World J. 2012;2012:167520.
Abdelaal M, le Roux CW, Docherty NG. Morbidity and mortality associated with obesity. Ann Transl Med. 2017;5(7):161.
Hamlington B, Ivey LE, Brenna E, Biesecker LG, Biesecker BB, Sapp JC. Characterization of courtesy stigma perceived by parents of overweight children with Bardet–Biedl syndrome. PLoS ONE. 2015;10(10):e0140705.
Kühnen P, Wabitsch M, von Schnurbein J, Chirila C, Mallya UG, Callahan P, et al. Quality of life outcomes in two phase 3 trials of setmelanotide in patients with obesity due to LEPR or POMC deficiency. Orphanet J Rare Dis. 2022;17(1):38.
Estrada E, Knox J, Reed C, Hadker N, Fay M, McCagg A. PDB109: burden of illness associated with hyperphagia and severe obesity. Value Health. 2019;22:S592.
Wabitsch M, Fehnel S, Mallya UG, Sluga-O’Callaghan M, Richardson D, Price M, et al. Understanding the patient experience of hunger and improved quality of life with setmelanotide treatment in POMC and LEPR deficiencies. Adv Ther. 2022;39:1–12.
Ervin C, Norcross L, Mallya UG, Fehnel S, Mittleman RS, Haqq AM, et al. Patient- and caregiver-reported experiences of hyperphagia in Bardet-Biedl syndrome before and during setmelanotide treatment. In: Presented at the pediatric endocrine society annual meeting; 2022 April 28–May 1; virtual.
Haws R, Brady S, Davis E, Fletty K, Yuan G, Gordon G, et al. Effect of setmelanotide, a melanocortin-4 receptor agonist, on obesity in Bardet–Biedl syndrome. Diabetes Obes Metab. 2020;22(11):2133–40.
Haqq AM, Chung WK, Dollfus H, Haws RM, Martos-Moreno GA, Poitou C, et al. Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period. Lancet Diabetes Endocrinol. 2022;10(12):859–68. https://doi.org/10.1016/S2213-8587(22)00277-7.
Imcivree (setmelanotide) [package insert]. Boston: Rhythm Pharmaceuticals, Inc.; 2022.
Varni JW. Scaling and scoring of the Pediatric Quality of Life Inventory: PedsQL. Version 20. Mapi Research Trust. https://www.pedsql.org/PedsQL-Scoring.pdf. Accessed 18 Mar 2022.
Varni JW, Seid M, Kurtin PS. PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations. Med Care. 2001;39(8):800–12.
Varni JW, Burwinkle TM, Seid M, Skarr D. The PedsQL 4.0 as a pediatric population health measure: feasibility, reliability, and validity. Ambul Pediatr. 2003;3(6):329–41.
Crosby RD, Kolotkin RL, Williams GR. An integrated method to determine meaningful changes in health-related quality of life. J Clin Epidemiol. 2004;57(11):1153–60.
Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971–84.
Varni JW, Limbers CA, Burwinkle TM. Impaired health-related quality of life in children and adolescents with chronic conditions: a comparative analysis of 10 disease clusters and 33 disease categories/severities utilizing the PedsQL 4.0 Generic Core Scales. Health Qual Life Outcomes. 2007;5:43.
Marschner N, Zacharias S, Lordick F, Hegewisch-Becker S, Martens U, Welt A, et al. Association of disease progression with health-related quality of life among adults with breast, lung, pancreatic, and colorectal cancer. JAMA Netw Open. 2020;3(3):e200643.
Oh TR, Choi HS, Kim CS, Bae EH, Oh YK, Kim YS, et al. Association between health related quality of life and progression of chronic kidney disease. Sci Rep. 2019;9(1):19595.
Buiting HM, Olthuis G. Importance of quality-of-life measurement throughout the disease course. JAMA Netw Open. 2020;3(3):e200388.